Back to top
more

VIVUS, Inc. (VVUS)

(Delayed Data from NSDQ)

$3.73 USD

3.73
58,550

+0.03 (0.81%)

Updated May 3, 2019 04:13 PM ET

After-Market: $3.83 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Better trading starts here.

Zacks News

VIVUS (VVUS) Loss Narrower than Expected, Revenues Up Y/Y

VIVUS Inc. (VVUS) reported a loss of 1 cent per share in the first quarter of 2017, which was narrower than a loss of 12 cents in the year-ago period as well as the Zacks Consensus Estimate of a loss of 13 cents

    VIVUS (VVUS) Down 14.1% Since Earnings Report: Can It Rebound?

    VIVUS (VVUS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

      VIVUS to Regain Commercial Rights for Stendra from Sanofi

      VIVUS, Inc. (VVUS) recently announced an agreement with Sanofi to reacquire the commercial rights to its erectile dysfunction drug, Stendrain Africa, the Middle East, Turkey and the Commonwealth of Independent States, including Russia.

        Orexigen Inks Commercialization Deal for Contrave, Stock Up

        Orexigen Therapeutics, Inc.'s (OREX) announced that it has entered into a commercialization and distributorship agreement with Italian pharmaceutical company, Bruno Farmaceutici, for its obesity drug, Contrave.

          VIVUS (VVUS) Beats on Q4 Earnings, Revenues Increase Y/Y

          VIVUS Inc. (VVUS) reported earnings of 54 cents per share in the fourth quarter of 2016 as against a loss of 12 cents in the year-ago period

            VIVUS Licenses Rights to PAH Drugs from Selten Pharma

            VIVUS, Inc. (VVUS) acquired exclusive global rights to develop and commercialize pulmonary arterial hypertension (PAH) drugs, tacrolimus and ascomycin from private biotech company, Selten Pharma, Inc.

              VIVUS (VVUS): Will Qsymia & Stendra Sales Improve in 2017?

              On Jan 3, we issued an updated report on VIVUS, Inc. (VVUS).

                4 Biotech Stocks with Bright Prospects in 2017

                Even as the drug pricing issue continues to plague the biotech sector, investors should find it safe to bet on these top-ranked biotech stocks that also have superb Style Score as markets roll into 2017.

                  5 Top Performing Biotechnology Stocks of November

                  November was a great month for pharma/biotech stocks after a rather difficult year when the industry struggled with media and political focus on high drug prices.